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Summary  
Uncoupling of oxidative phosphorylation (OXPHOS) in brown adipose tissue can be used by 
hibernating animals to produce heat at the expense of their fat mass. In a recent work, Dr 
Shulman and collaborators generated a liver-targeted derivative of the prototypical OXPHOS 
uncoupler 2,4-dinitrophenol (DNP) that alleviated steatosis, hypertriglyceridemia and insulin 
resistance in several model of nonalcoholic fatty liver disease and type 2 diabetes.    
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Oxidative phosphorylation (OXPHOS) is a fundamentalbiological process allowing the 
synthesis of mitochondrial ATP in most cells. During OXPHOS, energy production is coupled 
to the oxidation of endogenous substrates such as fatty acids and pyruvate. In some 
physiological situations, oxidation of these substrates can be uncoupled from ATP synthesis. 
This is for instance the case in brown adipose tissue (BAT) where OXPHOS uncouplingis a 
key mechanism whereby hibernators are generating heat to maintain a body temperature 
compatible with life[1,2]. OXPHOS uncoupling in BAT is mediated by the uncoupling 
protein-1 (UCP1), which isembedded within the inner mitochondrial membrane[1,2]. UCP1 
facilitates proton entry into the mitochondrial matrix, and thus the energy of the proton-driven 
membrane potential (Δψ) is dissipated into heat instead of being converted in ATP by the 
ATP synthase (Fig. 1A). Importantly, OXPHOS uncoupling is leading to a stimulation of 
substrate oxidation since this biochemical process is no longer controlled by ATP synthesis. 
In BAT, the preferred oxidative substrates are fatty acids that have been stored as 
triacylglycerol (TAG) molecules prior to hibernation[1,2] (Fig. 1A). At the end of the winter 
hibernating animals can lose as much as 40% of their body weight, mainly as fat mass, which 
has been burnt for thermogenesis[2-4].   
Many researchers working in the field of mitochondria are using for different purposes 
synthetic OXPHOS uncouplers such as 2,4-dinitrophenol (DNP) or carbonyl cyanide m-
chlorophenylhydrazone (CCCP). These compounds are also referred to as protonophoric 
uncouplers because their chemical structures allow the transport of protons across the inner 
mitochondrial membrane. Hence, DNP and CCCP can induce maximal mitochondrial 
respiration with different substrates including fatty acids, loss of the membrane potential 
Δψand abolition of ATP synthesis in isolated mitochondria and intact cells [5-7]. It is also 
noteworthy that different pharmaceuticals currently on the market can uncouple OXPHOS. 
Indeed, this has been shown with thelocal anesthetic bupivacaine, the antiarrhythmic agent 
amiodarone, the nonsteroidal antiestrogen tamoxifen and different nonsteroidal anti-
inflammatory drugs (NSAIDs)such as diclofenac, ibuprofen and salicylic acid [7-10]. 
Importantly, OXPHOS uncoupling can be an important mechanism whereby drugs can induce 
liver injury in some patients[10-12].  
The treatment of obesity and related metabolic disorders such as type 2 diabetes (T2D) and 
nonalcoholic fatty liver disease (NAFLD) is a matter of extensive investigations because these 
diseases are a major burden for public health and medical care systems.Regarding NAFLD, 
reduction of de novo lipogenesis and stimulation of fat oxidation are two major 
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pharmacological strategies that are currently tested [13,14].In particular, drug-induced 
increased fat utilization can be achieved by way of activation of peroxisome proliferator-
activated receptor- (PPAR), PPAR, and AMP-activated protein kinase AMPK[13-
17].Another strategy under investigation is the stimulation of mitochondrial fatty acid 
oxidation (FAO)by the OXPHOS uncoupler DNP and its derivatives DNP-methyl ether 
(DNPME), as proposed by Dr Shulman and collaborators[18,19].Indeed, this group already 
showed in 2004 that the treatment of obese rats for 3 days with low doses (16 mg/kg/day) of 
DNP alleviated fatty liver and hepatic insulin resistance [18].Furthermore, amelioration of the 
latter metabolic disturbance was accompanied with a normalization of the activity of protein 
kinase C- (PKC and c-Jun NH2-terminal kinase-1 (JNK1), two kinases impairing insulin 
signaling [18]. 
Although these early results were encouraging and demonstrated the effectiveness of this 
pharmacological strategy, the authors wished to develop a safer compound for further 
investigations [19]. Indeed, DNP was used in the 1930’s in different countries as a treatment 
of obesity butthis remedy was rapidly withdrawn from the market due to significanttoxicity 
[20]. For instance, severe hyperthermia, cardiovascular collapse and death were sometimes 
observed [21]. In addition, skin rashes, cataracts, agranulocytosis and neutropenia, deafness 
andliver injury with jaundice occurred in some patients[20,21]. Hence, although DNP-
inducedOXPHOS uncoupling and stimulation of mitochondrial FAO can alleviate obesity and 
fatty liver [18,20,21], its low therapeutic index and adverse effects preclude any registration 
to national drug agencies. 
In order to develop a safer OXPHOS uncoupler, Dr Shulman and collaborators thus 
generated 5 derivatives of DNP that could be metabolized to DNP by cytochromes P450 
(CYPs)[19]. Indeed, the working hypothesis was that hepatic biotransformation of the DNP 
derivatives to the parent compound would allow its local generation and consequently no (or 
minimal) OXPHOS uncoupling in extra-hepatic tissues (Fig. 1B). Hence, this strategy could 
minimize some side effects such as hyperthermia and cardiac dysfunction. These different 
compounds were screened for their ability to stimulate mitochondrial oxygen consumption in 
isolated hepatocytes with similar potencies to DNP. This screeningallowed selecting 2 
candidates but one of them was not retained because its physicochemical properties would not 
permit oral administration. Thus, DNP-methyl ether (DNPME) was selected for further in 
vivo investigations in rats.  
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A first set of investigations was performed in order to determine the safety profile of the 
selected molecule, as well as its ability to reduce liver TAG levels in rats fed a high-calorie 
diet[19]. From these experiments, it was found that a 5-day treatment with different doses of 
DNPME was far less toxic than DNP, in particular regarding liver and kidney injury as well 
as mortality. The dose of 5 mg/kg of DNPME was selected for further investigations since it 
was the lowest effective dose without significant toxicity. Importantly, other toxicological 
studies were carried out during 6 weeks and no deleterious effects were observed on the 
selected markers. Other investigations showed that after acute injection of 5 mg/kg of 
DNPME, DNP was found mainly in plasma, liver and kidney and to a lesser extent in heart, 
whereas much lower DNP levels were found in white adipose tissue (WAT), brain and 
skeletal muscles (quadriceps). In these experiments, it was noteworthy that DNPME was 
present at high levels in WAT compared to the other investigated tissues. Finally, a 7-day 
treatment with the same dose of DNPME showed a comparable kinetics profile with relatively 
high DNPME levels in WAT[19].Thus, it appears that DNPME is metabolized mainly in liver 
to DNP,whichundergoes renal excretion,and that DNPMEaccumulates in WAT. 
In order to determine whether DNPME (5 mg/kg) could be effective for the treatment of 
NAFLD and associated metabolic disorders, additional investigations were carried out in rats 
fed a high-fat diet with sucrose-supplementeddrinking water[19]. A first set of experiments 
showed that DNPME reducedpreexisting hypertriglyceridemia, hyperglycemia and 
hyperinsulinemia, as well as TAG levels in liver and quadriceps. Moreover, DNPME induced 
an early increase in mitochondrial FAO in liver but not in heart, quadriceps, brain and kidney. 
Interestingly, the authors found a 50% reduction in hepatic very-low-density lipoprotein 
(VLDL) production with DNPME treatment. This could explain, at least in part, why TAG 
levels were reduced in skeletal muscle despite the absence of mitochondrial FAO stimulation 
in this tissue. Other investigations showed that hepatic and muscle levels of diacylglycerol 
(DAG) were significantly reduced and this was associated with lowerPKC and PKC 
activity in liver and muscle, respectively.Moreover, DNPME-induced improvement of insulin 
sensitivity appeared to be related, at least in part, to the reduction of DAG levels since 
ceramide levels were unchanged in liver and muscle. Importantly, body weight, energy 
expenditure and food intake were unchanged during the 5-day period of DNPME treatment 
[19]. A second set of investigations was subsequently performed in two different rat models 
of T2D. In the first model, rats were fed a high-fat diet and treated with low doses of 
streptozotocin, an alkylating agent particularly toxic to the pancreatic beta cells [22]. In the 
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second model, Zucker Diabetic Fatty (ZDF) rats were fed a high-fat diet and sucrose-
supplemented drinking water. In both models, DNPME treatment reduced fasting plasma 
glucose, insulin and TAG levels as well as liver and quadriceps TAG content with no signs of 
hepatic or renal injury [19].  
Taking all these results into consideration, this study undoubtedly provides a 
majorbreakthrough in the treatment of NAFLD. Indeed, activation of mitochondrial FAO is 
currently considered as a major strategy to alleviate NAFLD[13-17,23], although the effects 
observed with some drugs stimulating FAO were somewhat disappointing in patients. For 
instance, treatment with fibratesaffordedno (or minimal) effects onfatty liver in clinical 
studies[24,25], whereas these PPAR activators were efficient in different rodent models of 
NAFLD [13]. It is still unclear why fibrates seem less efficient in alleviating NAFLD in 
humans, but possible hypotheses include lower basal PPAR expression and/or lesser ligand-
induced PPAR transactivation activity [13]. Obviously, inter-species differences will not 
pose a problem with DNPME since the proton-drivenmembrane potential Δψ is a universal 
feature of mitochondria.  
As previously mentioned, treatment with DNPME for 5 days did not modify the body’s 
energy expenditure in treated mice [19]. Although this may suggest that DNPME has no 
major effect in BAT in the short term, it will be interesting to carry out further investigations 
in this tissue but also in beige adipose tissue (also referred to as inducible brown, brown-in-
white, or brite adipose tissue). Indeed, recent investigations in adult humans showed that 
brown and beige adipose tissues could be interesting targets to treat obesity and related 
metabolic diseases [26,27].  
Although the data presented by Dr Shulman et al. indicated that DNPME was devoid of 
apparent toxicity in the different rat models used in their study, further investigations will be 
required to better determine the safety profile of this molecule. Indeed, targeting DNP 
generation in the liver could avoid some side effects related to OXPHOS uncoupling such as 
hyperthermia and cardiac dysfunction, but not others that are more likelyidiosyncratic 
reactions(e.g. skin rashes, neutropenia…). Regarding OXPHOS uncoupling, it is noteworthy 
that DNPME tended to increase oxygen consumption in isolated mouse heart and kidney 
mitochondria [19]. Moreover, DNPME significantlyenhanced oxygen consumption in isolated 
mouse liver mitochondria[19]. These data thusindicate that DNPME isconverted to DNP 
within mouse mitochondria, at least in some tissues. For a safety concern, 
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additionalinvestigations would be warranted to find out whether DNPME could uncouple 
OXPHOS in mitochondria isolated from different human tissues.   
It would also be important to determine whether long-term treatment with DNPME could 
favor oxidative stress in liver. Indeed, several studies showed that mitochondrial FAO can 
generatesignificant amount ofreactive oxygen species (ROS) in different tissues including the 
liver [28-30]. ROS production during the mitochondrial FAO process seems to occur not only 
within the respiratory chain but also at the level of some FAO enzymes such as acyl-CoA 
dehydrogenases and ETF-ubiquinone oxidoreductase [30,31]. Importantly, ROS production 
by these mitochondrial FAO enzymes is relatively insensitive to the mitochondrial membrane 
potential Δψ and thus to OXPHOS uncoupling [30,31].It is also noteworthy that FAO-driven 
ROS production could be higher in NAFLD, in particular in nonalcoholic steatohepatitis 
(NASH) [32]. Indeed, this liver lesion is associated with significant impairment of the 
respiratory chain activity, which greatly favors the leakage of electrons and thus ROS 
overproduction[32,33]. It should also be pointed out that OXPHOS uncoupling appears to be 
an important mechanism of drug-induced liver injury [10-12], as previously mentioned. 
Another issue that would need further exploration with DNPME is the identification of 
metabolite(s) other than DNP. Indeed, CYP-mediated biotransformation can lead to numerous 
metabolites, even when the parent drugs are small-sized molecules [34,35].Although most of 
drug metabolites are harmless, CYPs occasionally generate reactive metabolites that can be 
highly hepatotoxic [35,36]. It is noteworthy that DNPMEis a structural analogue of anisole, 
which can be metabolized by CYPs to phenol and two different hydroxyanisole derivativesby 
way of O-dealkylation and aromatic hydroxylation, respectively[37]. Moreover, DNP has 
been shown to be metabolized to aminonitrophenol and diaminophenol, which could augment 
the activity of some CYP isoforms [38]. Hence,further investigations will be needed to 
identify the full spectrum of DNPME metabolites and to determine whether DNPME could 
interact with the biotransformation of some marketed drugs. This might be an important issue 
because obese patients are consuming on average more drugs than non-obese individuals [39], 
while polypharmacy increases the risk of drug-drug interactions [40]. Moreover, the activity 
of some CYPs are enhanced in NALFD and this could favor drug-induced liver injury in some 
patients [36,41].  
As alreadymentioned, DNPMEadministration in rats resulted initsaccumulationin WAT, 
whereas little amount of DNP was detected in this tissue [19]. Importantly, investigationsin 
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rodents and humans showed that CYPs are expressed at significant levels in WAT [42-44]. 
Moreover, CYP expression in this tissue can be increased by different lipophilicdrugssuch as 
phenobarbital and dexamethazone [42,43].Thus, further studies should be carried out to 
determine whether such co-medications could augment the biotransformation of DNPME to 
DNP in WAT, which mightinduce significant heat production and undesirable hyperthermia. 
Despite these potential issues, one can wish that DNPME will prove useful in obese patients 
for the treatment of fatty liver, a liver lesion that can progress to NASH, cirrhosis and 
hepatocellular carcinoma [45,46].  
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Legend of the figure  
  
Figure 1: Consequences of oxidative phosphorylationuncoupling on fat metabolism and heat 
production. Panel A. In the brown adipose tissue (BAT), uncoupling of oxidative 
phosphorylation (OXPHOS) is mediated bythe uncoupling protein-1 (UCP1), which is 
inserted within the inner mitochondrial membrane. UCP1 transfers protons (H+) across the 
inner mitochondrial membrane, thus stimulating the mitochondrial fatty acid oxidation (FAO) 
and generating heat. Indeed, during OXPHOS uncoupling,mitochondrial FAO is uncoupled 
from ATP production and thus the energy of the proton-driven membrane potential Δψis 
dissipated into heat instead of being used for ATP synthesis. This system is utilized by the 
hibernating animals to maintain a body temperature compatible with life. This is associated 
with a large decrease in the triacylglycerol (TAG) levels stored in adipose tissue because 
TAG are hydrolyzed into free fatty acids (FFA),which are subsequently used as fuel for the 
mitochondrial FAO pathway. Panel B. In liver, 2,4-dinitrophenol (DNP) is able to uncouple 
OXPHOS and stimulate mitochondrial FAO because this protonophoric uncoupler is able to 
transport protons across the inner mitochondrial membrane. In a recent work, Dr Shulman and 
collaborators generated a derivative of DNP, DNP-methyl ether (DNPME) that can be 
metabolized to DNP by cytochromes P450 (CYPs), thus allowing DNP formation principally 
in the liver[19].This local OXPHOS uncoupling avoids an increase in body temperature but 
leads to a reduction of TAG and diacylglycerol (DAG) levels in fatty liver. Alleviation of 
steatosis is also associated to a reduction of plasma hypertriglyceridemia (not shown) and 
insulin resistancein liver and skeletal muscle.  
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